New Study on the Effect of Scopoletin and Silver Nanoparticles of Fenugreek Extract as Pancreatic Cancer Inhibition Agents

Abstract

Pancreatic cancer is a highly aggressive and lethal form of cancer with limited treatment options. Therefore, exploring novel therapeutic strategies is crucial to improve patient outcomes. Researchers are currently investigating the potential therapeutic effects of scopoletin and silver nanoparticles on various diseases, including pancreatic cancer. Specifically, they have synthesized and characterized silver nanoparticles using fenugreek extract and tested different concentrations of these nanoparticles and scopoletin to determine their anti-cancer and anti-angiogenic properties. The aim is to identify the most effective dose that can reduce the levels of cyclooxygenase-2 (COX-2) and lactate dehydrogenase (LDH), which are markers associated with cancer progression. The study was performed in a laboratory setting, dividing the samples into three separate groups. The first group, known as the control group, consisted of 30 samples from healthy individuals of both genders, aged between 23 and 45 years. The second group included 30 male and female patients aged between 45 and 65 years, with stage II pancreatic cancer. Lastly, the third group comprised 30 male and female patients with stage III pancreatic cancer, aged between 52 and 79 years. This study found that, compared to the control group, patients with stage IΙ and stage IΙΙ pancreatic cancer experienced the greatest decrease in enzyme concentration at the concentration of the nanoparticle solution 2 ppm where the Cyclooxygenas-2 enzyme concentrations values were 2.43±0.22ng/ml, 3.04±0.31ng/ml and 1.59±0.06ng/ml, respectively. As for the concentration of the enzyme Lactate dehydrogenase, it was 1.20±0.02ng/ml, 1.14±0.02ng/ml and 0.85±0.18ng/ml respectively. Also, as compared to the control 1.97±0.17ng/ml, 1.72±0.10ng/ml, and 1.22±0.07ng/ml, the concentration of the scopoletin compound solution 8ppm results in the best reduction in COX-2 enzyme concentration As for the concentration of the enzyme LDH, it was 0.93±0.07 ng/ml, 0.97±0.11 ng/ml and 0.71±0.10 ng/ml In individuals with stage IΙ and stage IIΙ PC. The results of this research demonstrate that scopoletin compounds and Ag-NPs derived from Fenugreek extract function as anti-cancer and anti-angiogenesis agents by reducing the levels of cyclooxygenase-2 (COX-2) and lactate dehydrogenase (LDH) enzymes in the blood serum of individuals with stage II and stage III pancreatic carcinoma in Iraq.